Vanda Pharmaceuticals (VNDA) Reports In-Line Q1 EPS, Revenues Miss
Get Alerts VNDA Hot Sheet
Revenue Growth %: +59,101.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $62.67 million versus the consensus estimate of $68.5 million.
"Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZĀ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "In our clinical programs, we have made significant progress, reaching 85% randomization in our Phase III tradipitant study in gastroparesis and initiating a new clinical program for HETLIOZĀ® in delayed sleep phase disorder."
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Zura Bio (ZURA) Appoints Robert Lisicki as CEO, Reports FY23 Results
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!